To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@mail.nih.gov along with the following information:

  • Your name, title, and organization
  • Study Number and Study Title
  • The specific dataset(s) you are requesting
  • The intended use or purpose of the data
  • Willingness to comply with the NIDA Datashare Registration Agreement
Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-CPU-0003

Division
DTMC
HEAL Study
No
Investigator(s)
Louis Cantilena, Jr., M.D, Ph.D.
Title
Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681
Short Description
This is a human laboratory clinical pharmacology study to assess potential interactions between intravenous (i.v.) cocaine and RPR 102681 administered in 3 escalating doses.
Release Date
May 23, 2017
Description

The primary objective of this study is to determine if there are significant interactions between RPR 102681 treatment concurrent with i.v. cocaine infusions of 0 and 40 mg by measuring adverse events and cardiovascular responses [heart rate (HR), blood pressure (BP), and electrocardiogram (ECG)].

Keywords
cocaine
interaction
phase 1b
rpr102681
stimulant
Assessments
Addiction Research Center Inventory
Beck Depression Inventory
Blood Cocaine Level
Blood Study Agent Level
Brief Psychiatric Rating Scale
Brief Substance Craving Scale
Brief Symptom Inventory
ECG Monitoring
Profile of Mood States
Visual Analog Scales
Vital Signs Monitoring
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
ClinicalTrials.gov Link
CPU-0003 in NIH clinical trials registry